Real-time enrollment status for this down syndrome-associated alzheimer's disease (ds-ad) clinical trial
Current Status
Recruiting
Checked: October 21, 2026 at 12:08 PM UTC
| NCT Number | NCT07636811 |
| Recruiting Status | Recruiting |
| Condition | Down Syndrome-Associated Alzheimer's Disease (DS-AD) |
| Phase | PHASE2 |
| Target Enrollment | 58 participants |
| Active Locations | 4 sites in the US |
| Sponsor | Alnylam Pharmaceuticals |
| Last Updated on CT.gov | October 13, 2026 (1 week ago) |
As of October 21, 2026: Clinical trial NCT07636811 is currently recruiting participants. This phase2 study for down syndrome-associated alzheimer's disease (ds-ad) is actively seeking new participants at 4 locations across the United States. The study is sponsored by Alnylam Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07636811 is actively recruiting participants as of October 21, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 4 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07636811 was last updated 1 week ago (October 13, 2026). HelloStudys verifies this status automatically.